Literature DB >> 10903782

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity.

J Gong1, N Nikrui, D Chen, S Koido, Z Wu, Y Tanaka, S Cannistra, D Avigan, D Kufe.   

Abstract

Human ovarian carcinomas express the CA-125, HER2/neu, and MUC1 tumor-associated Ags as potential targets for the induction of active specific immunotherapy. In the present studies, human ovarian cancer cells were fused to human dendritic cells (DC) as an alternative strategy to induce immunity against known and unidentified tumor Ags. Fusions of ovarian cancer cells to autologous DC resulted in the formation of heterokaryons that express the CA-125 Ag and DC-derived costimulatory and adhesion molecules. Similar findings were obtained with ovarian cancer cells fused to allogeneic DC. The fusion cells were functional in stimulating the proliferation of autologous T cells. The results also demonstrate that fusions of ovarian cancer cells to autologous or allogeneic DC induce cytolytic T cell activity and lysis of autologous tumor cells by a MHC class I-restricted mechanism. These findings demonstrate that fusions of ovarian carcinoma cells and DC activate T cell responses against autologous tumor and that the fusions are functional when generated with either autologous or allogeneic DC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903782     DOI: 10.4049/jimmunol.165.3.1705

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.

Authors:  Jin-Kun Zhang; Jun Li; Juan Zhang; Hai-Bin Chen; Su-Biao Chen
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.

Authors:  R V Goddard; A G Prentice; J A Copplestone; E R Kaminski
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 3.  Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine.

Authors:  Hongmei Xu; Xuetao Cao
Journal:  Front Med       Date:  2011-12       Impact factor: 4.592

4.  Lenalidomide enhances anti-myeloma cellular immunity.

Authors:  Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal:  Cancer Immunol Immunother       Date:  2012-06-24       Impact factor: 6.968

Review 5.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

6.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

7.  Run-in phase III trial design with pharmacodynamics predictive biomarkers.

Authors:  Fangxin Hong; Richard Simon
Journal:  J Natl Cancer Inst       Date:  2013-10-04       Impact factor: 13.506

Review 8.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

9.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

10.  Allogeneic mRNA-based electrotransfection of autologous dendritic cells and specific antitumor effects against osteosarcoma in rats.

Authors:  Zhe Yu; Jixian Qian; Jiachang Wu; Jie Gao; Minghua Zhang
Journal:  Med Oncol       Date:  2012-07-28       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.